2433 search results found
The CDTI SICC Innvierte of investing in Innovation, along with Nanoligent INVEREADY BIOTECH IV PARALLEL, SCR, S.A. and INVEREADY BIOTECH IV, SCR S.A., in order to develop an oncological nanofármaco
Nanoligent biotechnology is developing therapies against the cancer using proteins organized in nanoparticles and lymphocyte coupled with drugs.The main objective of this company, led by Dr. Montserrat Cano and dr. Manuel Rodríguez Mariscal, is to develop new medicines anticancerosos directed towar...
The CDTI SICC Innvierte of investing in Innovation KIBO VENTURES FUND IV INNVIERTE, F.C.R.E., fund focused on business cyber DeepTech as artificial intelligence, robotics, climate, health, education and other disruptive technologies
The CDTI innovation, through its Innvierte initiative, has committed an investment of up to eur 73.5 million on KIBO VENTURES FUND IV INNVIERTE F.C.R.E., fund, managed by KIBO VENTURES PARTNERS, SGEIC, S.A. This new vehicle will focus especially on DeepTech business as artificial intelligence, cyber...
The CDTI Innovation search a spanish company to work with Egypt in an r & D on IA and IoT in industrial environments
The initiative is led by the companyTECNOWELLEand the universityOctober University for Modern Sciences and Artsand focuses on the implementation of IA and IoT simulation and monitoring industrial environments.The project poses several lines of collaboration:Codesarrollar test avant-garde.Integrate b...
Convening EuroHPC 2025
The present resolution is intended to adopt the procedure for granting direct aid from the year 2025 aimed at ‘ International collaborative projects ”, in the framework of the state programme “ transfer and partnership ” and “ internationalization ” of the state Plan of scientific resear...
The CDTI Innovation sponsors and participates in the 8th edition of Valencia Digital Summit 2025
In this edition 2025, Digital Valencia Summit brought together over 12,000 participants from more than 120 countries in a program with more than 600 rapporteurs, 3,000 startups, 800 investors and presence of large international corporations, consolidated as a key area of connection between compani...
Ayudas-Subvenciones2
Catalogue of CDTI subsidies:NEOTEC: to support the creation and consolidation of technology-based enterprises (EBTs) based on the creation of lines of I + D + i own.Aid for Technological Centres Cervera: to strengthen the technological centres which carry out applied research in Spain, as well as it...
The CDTI Innovation spanish companies seeking to develop with south korea an r & D related with the technologies of Artificial intelligence
The project aims to develop a system for the provision and monitoring of the production of solar energy based on Artificial intelligence (IA).The activity of r & D will focus on:Analysis of the market of renewable energy through IA.Definition of variables and data for computational analysis based ...
Ramón Rama, commercial director Measures: “ The support of the CDTI and the FEDER has enabled us to drive innovation-based educational IA ”
In a context in which educational digitalisation is expanding fast and artificial intelligence begins to redefine the learning models, the galician company But Sacrificing Tecnolóxica Consulting has developed a proposal: Estud-IA pioneer, a platform linked to the educational attainment with artific...
7Th Called for bilateral projects España-china r & D
Thursday, 23 octoberThe 7th joint call España-china within the framework of the international agenda CHINEKA (China & Spain Innovating Program) for the submission of proposals for technology cooperation in priority areas between spain and China.The CDTI E.P.E., entity, the ministry of Science, inno...
The CDTI SICC Innvierte of investing in Innovation ARTHEx Biotech, together with Invivo Ventures, F.C.R. and Columbus Life Sciences Fund III, F.C.R., to develop a new treatment of RNA for myotonic dystrophy
ARTHEx Biotech is a biotechnology company valenciana in clinical phase focused on the development of medicines from rna aimed for rare genetic neuromuscular disorders. Its major programme, ATX-01, is located in clinical evaluation for myotonic dystrophy type 1 (DM1) in the trial ArthemiR ™. The te...